G Zalcman Selected Research

Xanthogranulomatous Pyelonephritis

4/2018

Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

G Zalcman Research Topics

Disease

16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2022 - 01/2004
15	Neoplasms (Cancer) 09/2021 - 01/2000
11	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2000
4	Mesothelioma 12/2016 - 09/2006
4	Neoplasm Metastasis (Metastasis) 10/2016 - 01/2007
3	Malignant Mesothelioma 01/2022 - 10/2007
2	Pneumonia (Pneumonitis) 01/2018 - 01/2016
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 05/2015 - 01/2000
2	Adenocarcinoma 10/2007 - 11/2004
1	Brain Neoplasms (Brain Tumor) 01/2022
1	COVID-19 09/2021
1	Cytokine Release Syndrome 09/2021
1	Infections 09/2021
1	Xanthogranulomatous Pyelonephritis 04/2018
1	Urinary Tract Infections (Urinary Tract Infection) 01/2018
1	Dysbiosis 01/2018
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 05/2017
1	Hypertension (High Blood Pressure) 05/2017
1	Diarrhea 05/2017
1	Carcinoma (Carcinomatosis) 01/2016
1	Bronchiolitis 01/2016
1	Organizing Pneumonia 01/2016
1	Tuberculosis (Tuberculoses) 08/2014
1	Extensively Drug-Resistant Tuberculosis 08/2014
1	Adenocarcinoma of Lung 10/2007
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2007
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 02/2007
1	Carcinoid Tumor (Carcinoid) 01/2007
1	Pulmonary Atelectasis 01/2007
1	Thoracic Diseases 01/2007
1	Carcinogenesis 11/2006
1	Bronchogenic Carcinoma 11/2006

Drug/Important Bio-Agent (IBA)

5	Immune Checkpoint InhibitorsIBA 09/2021 - 01/2016
4	Pemetrexed (MTA)FDA Link 09/2022 - 10/2007
4	Cisplatin (Platino)FDA LinkGeneric 09/2022 - 02/2007
3	Cetuximab (Erbitux)FDA Link 09/2022 - 10/2008
3	Bevacizumab (Avastin)FDA Link 05/2015 - 02/2007
3	Biological ProductsIBA 10/2008 - 11/2006
2	NivolumabIBA 01/2022 - 01/2016
2	CrizotinibIBA 12/2019 - 04/2018
2	Monoclonal AntibodiesIBA 11/2018 - 10/2008
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2018 - 08/2014
2	Tyrosine Kinase InhibitorsIBA 06/2011 - 11/2006
2	PlatinumIBA 04/2011 - 01/2004
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2007 - 11/2006
2	AntibodiesIBA 01/2001 - 01/2000
1	IpilimumabIBA 01/2022
1	lorlatinibIBA 01/2022
1	Messenger RNA (mRNA)IBA 09/2021
1	VaccinesIBA 09/2021
1	Anaplastic Lymphoma KinaseIBA 12/2019
1	LigandsIBA 11/2018
1	durvalumabIBA 11/2018
1	LactamsIBA 01/2018
1	QuinolonesIBA 01/2018
1	Transaminases (Aminotransferases)IBA 05/2017
1	Focal Adhesion Protein-Tyrosine KinasesIBA 12/2016
1	Neurofibromin 2 (Merlin)IBA 12/2016
1	GSK2256098IBA 12/2016
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2016
1	SteroidsIBA 01/2016
1	Gemcitabine FDA Link 11/2014
1	iniparibIBA 11/2014
1	Pharmaceutical PreparationsIBA 08/2014
1	ErbB Receptors (EGF Receptor)IBA 01/2011
1	AsbestosIBA 10/2007
1	pentetreotide (OctreoScan)FDA Link 01/2007
1	Platinum Compounds (Compounds, Platinum)IBA 11/2006
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2006
1	TubulinIBA 11/2006
1	Gefitinib (Iressa)FDA Link 11/2004
1	Docetaxel (Taxotere)FDA Link 01/2004
1	Biomarkers (Surrogate Marker)IBA 10/2002
1	Tumor Protein p73IBA 01/2001

Therapy/Procedure

12	Drug Therapy (Chemotherapy) 01/2022 - 01/2004
8	Therapeutics 01/2019 - 11/2006
5	Radiotherapy 09/2022 - 09/2006
3	Biological Therapy 11/2006 - 10/2002
2	Immunotherapy 01/2019 - 01/2016
1	Injections 09/2021
1	Time-to-Treatment 01/2021
1	Induction Chemotherapy 05/2015
1	Collapse Therapy 08/2014
1	Adjuvant Chemotherapy 09/2006